BioSpace News Archive

Financial Condition for Initial $5 Million Tranche of Potential $16 Million Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann

Atrility Medical today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AtriAmp™ Device. The AtriAmp facilitates more efficient monitoring and treatment of atrial arrhythmias, a common side-effect of many heart surgeries.

Today, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Acadia Pharmaceuticals announce a partnership to provide free educational materials to patients and their care partners.

Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies from the Bill & Melinda Gates Foundation

Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis.

Scientific Industries, Inc. (OTCQB:SCND), a life science tool provider, is scheduled to participate in a virtual presentation and fireside chat at the October 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, October 7, 2020 at 4:00 p.m. ET (1:00 p.m. PT).

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with its partner ADS Biotec announce the launch of the beta phase testing for its new IV-cell cytogenetics culturing media.

AccessHope TM remotely connects patients to expertise from world-renowned national comprehensive cancer center, providing unparalleled decision support to patients and their treating physicians.

Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. (Nasdaq:BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS

USWM, LLC, a Kentucky-based specialty biopharmaceutical company, announced an additional donation as part of their partnership with the Federal Emergency Management Agency and Healthcare Ready.